Moderna’s Strategic Shift and Financial Outlook Leads to Sell Rating and Lowered Price Target
Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...